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ABSTRACT 
EGFR overexpression is associated with squamous cell carcinoma development. Altered 
endocytosis and polarization of receptor tyrosine kinases, including EGFR, affect migration 
and invasion in 3D culture. These studies have been completed via genetic sequencing, cell 
line or 3D in vitro and in vivo murine models. Here we describe an imaging method that 
allows ex-vivo examination of ligand-induced endocytosis of EGFR in non-dissociated human 
tumours. We analyzed sets of tumour samples from advanced cutaneous squamous cell 
carcinoma and Head and Neck squamous cell carcinoma, actinic keratosis, intra-epidermal 
carcinoma and cutaneous squamous cell carcinoma. We demonstrate that EGFR endocytosis 
is dysregulated in advanced SCC and correlates with anti-EGFR monoclonal antibody therapy 
outcomes. In actinic keratosis, intra-epidermal carcinoma and well-differentiated cutaneous 
squamous cell carcinoma different patterns of epidermal growth factor ligand uptake and 
binding were observed at the leading edge of different dysplastic lesions, suggesting that these 
differences in EGFR endocytosis might influence the metastatic potential of dysplastic 
squamous epithelium. These studies in live ex-vivo human tumours confirm that endocytosis 
dysregulation is a physiological event in human tumours and has therapeutic implications. 
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INTRODUCTION:  
 
The Epidermal Growth Factor Receptor (EGFR) is a receptor tyrosine kinase required for skin 
development and homeostasis (Jost et al., 2000). However, dysregulation of EGFR function 
results in cellular hyper-proliferation, defects in wound healing, development of psoriasis-like 
lesions, defects of the hair follicles and tumourigenesis (Pastore et al., 2008). The role of 
EGFR in cancer initiation has led to the use of therapeutic EGFR inhibitors (Van den Eynde 
et al., 2011). EGFR signaling is controlled not only by ligand binding and activation, but also 
by localization in plasma membrane domains and internalization by receptor-mediated 
endocytosis.  EGFR internalization is clathrin and dynamin-dependent in vivo in murine 
models (Pinilla-Macua et al., 2017) and dysregulation and heterogeneity of endocytosis may 
be a factor in delineating patient therapeutic responses (Elkin et al., 2016, Mellman and 
Yarden, 2013). 
 
EGFR is over-expressed in ~45% of cutaneous squamous cell carcinomas (cSCC) (Canueto et 
al., 2017, Ch'ng et al., 2008) and over 98% Head and Neck squamous cell carcinoma 
(HNSCC) (Grandis and Tweardy, 1993). Despite this, therapeutic antibodies that target EGFR 
have improved survival in only ~15% of patients treated as a monotherapy (Vermorken et al., 
2008), but display higher efficacy in combination with radiotherapy (Bonner et al., 2006). 
High EGFR expression is observed at the infiltrating edge of primary SCC (Groves et al., 
1992, Jost et al., 2000, Kikuchi et al., 1990).  Whilst reviewing current literature we noted that 
studies showed variation in EGFR expression and localization from actinic keratosis (AK) to 
squamous cell carcinoma (SCC) (Gaffney et al., 2014). One study reported a negative 
correlation between the degree of SCC differentiation and expression of EGFR (Liu et al., 
1996) and EGFR overexpression does not correlate with poor differentiation (Lavrijsen et al., 
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1989). EGFR expression may relate to the degree of dysplasia of the individual cells in an 
SCC or keratinocyte lesion (Nazmi et al., 1990). Importantly, neither total nor surface 
expression of EGFR predicts response to treatment with anti-EGFR drugs in SCC and EGFR 
expression does not consistently correlate with disease progression (Chung et al., 2009, 
Helman et al., 2010, Wheeler et al., 2010).  
 
We have used advanced imaging techniques to study the kinetics of epidermal growth factor 
(EGF) ligand binding and endocytosis in ex vivo human skin tumour samples. We 
demonstrate that in a proportion of advanced SCC tumours, EGFR does not undergo 
endocytosis in response to ligand stimulation, and that this dysregulated endocytosis 
correlates with improved outcomes to anti-EGFR therapy. AK, intra-epidermal carcinoma 
(IEC) and cSCC displayed heterogeneous EGFR trafficking, which in some cells was also 
polarized, suggesting that this may be an early event in tissue dysplasia. 
 
RESULTS: 
Confocal microscopy correlates with conventional histopathology for human AK to 
cSCC analysis 
We developed a method of fixing and analyzing un-dissociated tissue by confocal 
microscopy.  Prior to selection of un-dissociated tissue, serial sections of human biopsies 
were stained, either by traditional H&E or processed for confocal microscopy. Confocal 
images were matched with an expert pathologist’s identification of sample elements and 
defined as normal, AK, IEC or SCC, as allowed identification of disseminated SCC.   As 
shown in Figure 1a, confocal images and H&E staining comparisons showed tissue features 
clearly matched. The epidermis is thin and there is a layer of normal orthokeratosis.  There is 
a well-demarcated basal layer with no invasion or inflammatory infiltrate visible. 
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Immunostaining of normal tissue showed the corneocyte envelopes were strongly 
autofluorescent in the red emission spectrum and therefore were discounted as specific 
staining in further analysis (Supplementary Fig. S1). Other tissue areas showed low 
background. Figure 1b demonstrates correlation of EGFR localization with H&E staining and 
shows that EGFR immunostaining is specific for tumour cells (normal matched tissue shows 
no uptake) within the ex-vivo tissue (dotted lines demarcate tumour tissue as identified by 
H&E) consistent with EGFR overexpression in SCC (Canueto et al., 2017, Ch'ng et al., 2008, 
Grandis and Tweardy, 1993). It should be noted that standard H&E and confocal shown here 
are sectioned as per normal practice. However, all EGF ligand uptake experiments shown in 
subsequent Figures are performed on serial “lumps” of live tumour tissue as documented in 
Supplementary Figure S2 with multiple lumps analyzed for each condition across the tumour 
sample allowing assessment of potential variation within tumour sample.  
 
EGFR ligand-induced endocytosis is dysregulated in live ex vivo SCC with locally 
advanced, locoregionally recurrent or distant metastatic disease.   
 
An assay was developed to assess ligand-induced internalization of the EGFR in live non-
dissociated ex-vivo tumour biopsies. Briefly, tumour biopsies freshly removed from 
consenting patients were incubated in serum-free media on transfer to the research laboratory. 
Samples were processed within 30 minutes of biopsy procedure. EGF ligand directly 
conjugated to Alexa Fluor488 (EGF-Alexa488) was added to multiple small sections of tumour 
biopsy samples (as described in Supplementary Fig. S2) for 0, 15, 30 and 60 minutes 
respectively (15 and 30 minutes shown Fig. 2) along with additional controls to ensure uptake 
is specific (Fig. 3). Ligand-induced endocytosis was halted at the appropriate time-point by 
washing in ice-cold PBS followed by PFA fixation. Tumour samples were processed as per 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 
 
materials and methods (and Supplementary Fig. S2). This technique allowed us to assess the 
rate of uptake of surface-exposed EGFR rather than observing steady-state distribution. This 
sample preparation also allowed us to analyze multiple areas of the tumour samples per 
condition.  
 
Ligand-induced internalization was analyzed by confocal microscopy. In advanced SCC we 
found only two patterns of EGF ligand uptake; either internalized or one hundred percent 
blocked on the cell surface (endocytically dysregulated). Figure 2a and 2b show EGF-
Alexa488 uptake after 15 minutes and 30 minutes for two different patient lesions. Patient SCC 
AC3P lesion (Fig. 2a) shows efficient EGF-Alexa488 uptake with punctate staining, whereas 
Patient SCC DP5 lesion (Fig. 2b) shows EGF-Alexa488 that is endocytically dysregulated and 
blocked at the plasma membrane. The matched normal tissue showed minimal EGF-Alexa488 
ligand uptake and some cells displayed low level nuclear staining (Brand et al., 2011). The 
escape of receptor tyrosine kinases from endocytosis has been proposed as a new “hallmark of 
cancer” (Mellman and Yarden, 2013) and this phenomenon was observed in some SCC 
samples (Fig. 2b) that did not internalize EGF ligand. Analysis of tumour samples by three 
dimensional structured illumination (super resolution) microscopy (3D-SIM) (Huang et al., 
2009) clearly shows the EGFR trafficking differences within patient samples. Figure 2c (top) 
shows a patient lesion whose EGFR does not undergo EGF-induced internalization and only 
plasma membrane localization can be observed whereas Fig. 2c (bottom) shows a normally 
internalizing EGFR patient lesion, where the cell endosomes can be clearly observed. 
Twenty-four samples of SCC with locally advanced, locoregionally recurrent or distant 
metastatic disease were analyzed for EGF ligand uptake localization and EGFR trafficking 
status is summarized in Table 1; 13/24 (~54%) showed EGF ligand internalization whereas 
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11/24 (~46%) showed dysregulated EGFR internalization.  Samples not expressing EGFR 
were not included in the study.  
 
Figure 3a demonstrates co-localization between EGF-Alexa488 and EGFR at the plasma 
membrane, as evidenced by the cobblestone like pattern typical of plasma membrane staining 
in epithelial cells (Chua et al., 2009, McCluskey et al., 2013, Pinilla-Macua et al., 2017, 
Pinilla-Macua and Sorkin, 2015) showing that EGF ligand imaging is specific.  Additional 
controls were also carried out including pre-incubation with anti-EGFR monoclonal antibody 
(cetuximab) to block EGF-Alexa488 binding and allow EGFR binding specificity to be 
assessed (Fig. 3b), EGF-Alexa488 incubation at 4oC to inhibit endocytosis (not shown) and 
addition of DEAE-Dextran-Alexa594 to show that cells are capable of fluid-phase uptake and 
not necrotic areas of the tumour (Fig. 3c). Figure 3b addresses directly the specificity of EGF 
uptake. Cetuximab binds specifically to the EGFR, preventing EGF-Alexa488 ligand binding. 
Thus this level was used as the baseline over which fluorescent signal was judged to be 
specific so only EGF-Alexa488 staining above any fluorescence from a cetuximab pre-
incubation control are shown in any result. This may reduce signal but ensures all 
demonstrated staining is specific. Figure 3c shows live ex vivo tumour samples following 
addition of EGF-Alexa488 and DEAE-Dextran-Alexa594. This illustrates that cells are capable 
of fluid-phase uptake and not necrotic. EGF-Alexa488 and DEAE-Dextran-Alexa594 partially 
co-localized (Fig. 3c; arrows) confirming an internalized localization.  We noted that dextran-
containing compartments are more punctate in the endocytically competent samples. This 
would fit with a more general block in endocytosis in the dysregulated samples as opposed to 
a specific block in EGFR endocytosis alone. 
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Further co-staining of EGF-Alexa488 with the early endosome marker, EEA1, (Fig. 3d) 
showed some co-localization or juxtaposition of immunostaining (arrows) in the internalizing 
lesions but not within endocytically dysregulated lesions. Additionally, the internalization 
competent lesions showed increased EEA1 labeled endosomes. Co-labeling of EGF-Alexa488 
with clathrin (Fig. 3e) demonstrated that in tumour samples in which EGFR failed to 
internalize, clathrin recruitment to the plasma membrane was decreased in response to EGFR 
ligand stimulation.  Together this data shows that ligand induced internalization of EGFR is 
blocked in some patients. This may be associated with more widespread changes in protein 
internalization and trafficking processes as indicated by differences seen for dextran uptake, 
EEA1 and clathrin immunostaining.  
 
EGFR ligand-induced trafficking competence correlates with patient response to 
therapy 
For some of the advanced cSCC samples, we had the opportunity to examine biopsies of 
patients recruited to a Phase II clinical trial of panitumumab (anti-EGFR monoclonal) therapy 
(Foote et al., 2014).    Patients received single agent panitumumab and analysis of this group 
was not confounded by synergism between radiation therapy (RT).  Of the sixteen EGFR 
positive patients, twelve consented to pre-treatment biopsies for EGFR trafficking status 
analysis. EGFR trafficking categorization was completed pre-treatment and pre-unblinding of 
results. Of the twelve samples, six were categorized as internalizing and six as endocytically 
dysregulated (blocked). On data release the results were correlated with Response Evaluation 
in Solid Tumour (RECIST v 1.1) as summarized in Table 1 (according to (Foote et al., 2014)). 
All six patients that had tumours categorized as internalizing had died from progressive 
disease at trial conclusion. Of the six patients that had tumours categorized as endocytically 
dysregulated, five showed a rash associated with response to anti-EGFR monoclonal antibody 
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therapy. One patient showed Complete Response and four were categorized as Alive with 
Stable Disease. The remaining patient, with tumours categorized as endocytically 
dysregulated, died prior to assessment from unrelated renal transplant complications. We 
additionally correlated outcomes for five metastatic HNSCC patients who underwent 
cetuximab treatment; four patient tumours were categorized as internalizing and these patients 
had poor outcomes and one patient tumour categorized as endocytically dysregulated had a 
positive Complete Response. Six patients had no anti-EGFR therapy and outcomes were not 
determined. In total, we show that of seventeen assessable patients receiving either cetuximab 
or panitumumab (anti-EGFR therapy), ten internalized EGFR and had poor clinical outcomes 
whilst seven did not internalize EGFR (endocytically dysregulated) and had good outcomes. 
A strong association (Fisher exact test 0.0001, p<0.05) exists between EGFR internalization 
and poor therapeutic response/survival to EGFR therapeutic antibody therapy. We conclude 
that SCCs can be classified based on their ability to internalize or not internalize EGFR in 
response to ligand. We have since found that the correlation with anti-EGFR therapy response 
is due to an impact on antibody dependent cellular cytotoxicity (ADCC) (Echejoh et al., 
2018). 
 
This may also have implications for EGFR mediated cell signaling from the plasma 
membrane and this was examined in 2D SCC cultures (Supp. Fig. S3 and S4).  No cell line 
showed the complete escape from EGFR internalization observed in advanced cSCC and no 
correlation was observed between EGFR levels/internalization nor a clear relationship 
between constitutive phosphorylation of the EGFR and EGFR internalization rate/capacity or 
between expression/activation of ERK and AKT in response to EGF binding (Supp. Fig. S3 
and S4).  Thus the 2D cell lines could not be used to reflect the physiological events. 
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Characterization of AK, IEC’s and SCC biopsy samples 
We went on to analyze early and non-invasive lesions; AK, IEC and cSCC. Fifty-six biopsies 
were excised in Princess Alexandra Hospital (PAH) Dermatology departments and biopsies 
characterized as described in Supplementary Table S1. Twenty-four lesions were discarded 
after the initial stage due to alternative histopathological diagnosis.  Thirty-two samples were 
confirmed by expert histopathological analysis as being AK, IEC’s or SCC that were of 
study-appropriate type.  Three lesions were discarded as no recognizable epidermis or tumour 
tissue was seen on initial microscopy.  All included lesions were subsequently reviewed by a 
dermatopathologist.  Lesions composed predominantly of regenerative epidermis rather than 
squamous neoplasm were excluded.  To create uniform classification for this study, lesions 
were also reclassified and reassigned a grade of differentiation to exclude the variability 
between pathologists present from the initial pathology reports.   This resulted in 26 lesions 
with diagnosis and grade as per a single uniform classification as summarized in 
Supplementary Table S2.  All AK were well differentiated and no IECs or superficial SCCs 
were classified as poorly differentiated.  To complement and categorize the ex-vivo live tissue 
analysis, researchers and expert pathologist reviewed confocal 25X images of slides from 
each lesion alongside representative histology H&E slides. The tumour region assessed by 
confocal microscopy was required to be consistent in appearance with the lesion on H&E 
slide for continued study.  Three lesions were discarded at this stage. To clarify, this data 
from pathology is complementary and a control for the analysis of the ex-vivo tissue as shown 
in Supp. Figure S2, conducted to ensure correct diagnosis and analysis of the correct 
specimen.  The final count resulted in 23 lesions assessed for EGF trafficking status by 
analyzing EGF-Alexa488 ligand uptake by confocal analysis.  Of the 32 total samples, 23 of 
which were defined tumour region samples, 17 highly expressed the EGFR and therefore the 
trafficking status of the EGFR could be determined. At the level of confocal microscopic 
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analysis 53% of samples showed high expression of EGFR. This agrees with the published 
immuno-histochemical staining value of ~45% (Canueto et al., 2017, Ch'ng et al., 2008). 
   
AK, IEC and SCC lesions show differential endocytosis patterns and polarized  
trafficking of EGF ligand. 
Of the 23 pre-metastatic lesions expressing high levels of EGFR, EGF-Alexa488 uptake status 
was determined in 17 lesions. These AK, IEC and SCC tumour samples were incubated with 
EGF-Alexa488 ligand and EGF ligand localization was analyzed using confocal microscopy; 
some tissues had EGF ligand internalized and some had EGF ligand blocked (dysregulated) 
on the cell surface or a combination of both. Time courses for EGF ligand uptakes are shown 
in Supplementary Figure S5 and S6. For an internalizing lesion (Supp. Fig S5), maximal 
EGF-Alexa488 ligand uptake was observed at 30 minutes with EGF-Alexa488 showing a 
punctate distribution. For an EGFR dysregulated lesion (Supp. Fig. S6), maximal EGF-
Alexa488 ligand binding could be seen at 30 minutes with EGF-Alexa488 blocked at the plasma 
membrane. Pre-incubation of lesions with cetuximab blocked EGF-Alexa488 ligand uptake 
confirming EGF-Alexa488 ligand internalization/binding was EGFR specific (Supp. Fig. S5 
and S6; cetuximab+30min).  For lesions with both internalizing or dysregulated EGFR 
trafficking no significant level of EGF-Alexa488 uptake could be detected in normal skin, 
including normal UV-exposed skin from areas surrounding lesion/SCC biopsy sites as shown 
in (Supp. Fig. S5b and S6b).  
 
The EGF-Alexa488 uptake status (internalizing or dysregulated localization) was analyzed in 
17 lesions, data is summarized in Supplementary Table S3.  In contrast to advanced SCC 
(Fig. 2 and Table 1), AK, IEC and cSCC showed variation in the degree of ligand blocked on 
the cell surface or internalized within the lesion. Therefor the localization was quantified by 
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having non-project related staff blindly count linear (surface) versus dispersed (punctate) 
pixels (blind count) in each tumour image that corresponded to dysregulated or internalizing 
EGF ligand localization, respectively. Quantitation is shown in Supplementary Figure S7 and 
corresponding patient demographics are shown in Supplementary Table S2 and S3.  Overall, 
11/17 lesions (~65%) showed internalizing EGFR whereas 6/17 (~35%) lesions had 
dysregulated EGFR trafficking, with a cut-off of 70% linear. Increased EGFR expression and 
EGF-induced internalization could be detected in AK as well as those of IEC and in 
moderately and well-differentiated SCC.  In each of these stages there was evidence of 
dysregulation of EGFR ligand-induced internalization.   
 
Early stage lesions (AK, IEC and SCC samples) were removed from patients as per standard 
clinical care, we cannot assess any correlation between EGF ligand endocytosis distribution 
and AK/IEC/SCC progression.  When considering patient history it may be noted that all 
lesions that had dysregulated EGF ligand uptake had a patient history of greater than 5 SCC 
removed and/or had high risk host features (Supp Table S2 and S3). 
 
Variation in localization of EGF-Alexa488 within AK, IEC and SCC lesions was also noted to 
occur within cells at the tumour margin (Fig. 4). In some earlier stage lesions, EGF ligand 
was polarized to the leading edges of the tumour cells at their forward boundaries, exhibiting 
both internalized and dysregulated EGFR. In this instance we define polarization on a single 
cell level, where in a cell which internalizes EGFR, this uptake is only occurring at one area 
of the cell and not across the entire cell plasma membrane as reported in 3D cultures (Belleudi 
et al., 2011, Mutch et al., 2014). The predominant uptake of EGF-Alexa488 appeared to occur 
near the basal layer at the leading edge of the tumour. In some samples non-polarized EGF-
Alexa488 ligand localization was observed for both internalizing and dysregulated lesions. The 
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intensity of EGF-Alexa488 ligand uptake or binding also varied between tissues, which may 
reflect EGFR expression levels. Examples of each of the observed sub-patterns of EGF 
ligand/EGFR endocytosis seen in patients’ tumour samples are shown in Figure 4.   
 
DISCUSSION 
Post-fixation immunohistochemistry or other tissue section methods do not show changes in 
rates of internalization. Additionally, antibodies used to label EGFR are high affinity and 
avidity and provide a saturating signal that may mask differences in receptor distribution. 
Here we describe an assay whereby internalization of EGF-Alexa488 can be measured in live 
ex-vivo tissue over a time-course of uptake and we image ligand internalization, at high 
resolution, in living human cancer tissue. The small amount of EGF ligand used ensures 
uptake via clathrin-mediated endocytosis (Pinilla-Macua et al., 2017) and is below saturation 
levels of signal as no secondary antibody amplification is used. The assay can be carried out 
in ex-vivo live human tumours thus effects of local cytokines, growth factors, tissue position, 
the local inflammatory or immune environment and other signals which may affect EGFR 
localization or internalization are present, in contrast to tissue culture or xenograft models. 
We show that 11/24 (~46%) of human SCC with locally advanced, locoregionally recurrent or 
distant metastatic disease samples displayed inherent defects in ligand-induced EGFR 
internalization.  
 
In ~46% of advanced SCC we find that the EGFR no longer undergoes ligand-induced 
endocytosis. Recent work by Elkin et al (Elkin et al., 2016) reported that slowing of 
endocytosis was observed in a number of non-small cell lung carcinoma (NSCLC) cell lines 
and mutations and defects in numerous pathways such as the Cbl ubiquitination pathway have 
been reported to inhibit endocytosis of receptor tyrosine kinases in cancer (Mellman and 
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Yarden, 2013). In advanced invasive ex vivo samples initially it is unlikely that the defects in 
EGFR internalization define tumour initiation events. However, differential localization and 
dysregulation of endocytosis was observed in early and non-invasive lesions, including AK. 
One of the disconnects in the studies of EGFR in cancer is that while EGFR is an oncogene 
and involved in tumour initiation, in fully formed tumours there is no clinical correlation 
between tumour growth nor with patient outcome. However, there is a clinical correlation 
between EGFR and metastasis (reviewed in (Feigin and Muthuswamy, 2009)).  
 
The anti-tumour actions of anti-EGFR monoclonal antibodies involve multiple mechanisms 
including signaling inhibition, and cytotoxicity via immune system-dependent mechanisms 
such as ADCC (Hara et al., 2008, Kawaguchi et al., 2007, Kimura et al., 2007, Kurai et al., 
2007). ADCC has been shown to be the main clinical response mechanism in patients. Based 
on our findings presented here we have found that improved clinical responses to EGFR-
directed therapeutic antibodies for patients that had blocked EGFR internalization are due to 
an increase in EGFR clustering on the plasma membrane, leading to increased ADCC 
(Echejoh and Hu et al, manuscript submitted) and in agreement with Kim et al (Kim et al., 
2017). 
 
Our observations show that EGFR trafficking can become polarized within individual cells 
that are at the external tumour areas near the basal cell layer. While outcomes for patients who 
have had early lesions removed are not reported (as surgery is curative), we note that two of 
the highly polarized EGFR pattern patients were the two whom did return with advanced SCC 
(Supplementary Table 3, asterisk). It has been demonstrated in 3D tissue culture models that 
the polarization of endocytosis of EGF bound to EGFR is necessary for EGF-directed 
chemotactic invasion by cancer cells. The polarized endocytosis of both Keratinoctye Growth 
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Factor Receptor and EGFR may re-model the cellular machinery to allow cell migration and 
invasion (Belleudi et al., 2011, Mutch et al., 2014). Loss of EGFR internalization in a subset 
of SCC lesions may have consequences for EGFR-coupled signaling events. Effects on 
signaling of the EGFR from the plasma membrane versus internal compartments such as 
endosomes have been reviewed previously (Ackerman and Mones, 2006, Avraham and 
Yarden, 2011, Kolch, 2000, Mellman and Yarden, 2013, Teis and Huber, 2003). More 
specifically, attenuation of EGFR localization at the plasma membrane during a block in 
endocytosis was shown to lead to increased cell proliferation and a decrease in ERK 
phosphorylation (Avraham and Yarden, 2011, Kolch, 2000, Teis and Huber, 2003). However, 
our analysis of 2D SCC cell cultures showed that defects in receptor trafficking do not 
directly correlate with obvious signaling signatures (Supp. Fig. S3 and S4). 
 
EGFR acts as a cellular motility and migration cytokinetic sensor during embryonic 
development (Olayioye et al., 2000). We speculate that in early stages of SCC development, 
as EGFR levels and constitutive phosphorylation increase in response to UV exposure, the 
EGFR may also function in its developmental capacity. Since the cellular cytokinetic 
response of EGF binding to the EGFR is migration and metastasis, the potential for cells 
expressing high levels of polarized EGFR trafficking to undergo deep invasion through the 
basal cell layer may be high. It will be interesting to determine in larger cohorts of patients 
whether AK with highly polarized EGFR endocytosis in cells adjacent to the basal cell layer 
have more progressive and metastatic potential. 
 
Polarization is most likely to be a response to a local cytokine, either a growth factor or 
inflammatory cell cytokine release. EGFR activation is responsible for the cellular secretion 
of proteins involved in anti-microbial defense (Pastore et al., 2008). A number of single-
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nucleotide polymorphisms identified as predictive for anti-EGFR therapy are involved in the 
trafficking and internalization of EGFR, including polymorphisms in c-CBL and EPS15 
(Stintzing et al., 2015), suggesting that polarization or dysregulation of EGFR trafficking may 
in part determine patient therapeutic response. 
 
In conclusion, by analyzing the kinetics of EGF ligand binding and endocytosis in ex vivo 
human skin tumour samples we demonstrate that endocytosis is highly dysregulated in AK, 
IEC’s and SCC and in advanced SCC and this may have implications for therapy and the 
propensity for invasion of SCC down through the basal cell layer. 
 
MATERIALS AND METHODS 
Tumour samples were collected with written patient informed consent and Metro South 
Health ethics approval (HREC/11/QPAH/034; HREC ref: 2009/098; HREC/99/QPAH/34) on 
ice. For histology, paraffin embedded serial sections of biopsies were stained traditionally by 
H&E or by whole mount immunofluorescence. The declaration of Helsinki protocols were 
followed. 
 
EGF ligand internalization assay using fresh human tumour samples.  
For confocal microscopy of whole mount tissue samples, transverse sections of unfixed 
tumours were sliced into pieces of approximately 2x2x0.5-1.0mm by hand and washed three 
times for 10minutes in serum-free media (Ham’s F-12 media: DMEM; Gibco, Invitrogen) at 
4oC. Multiple tumour lumps were then incubated in Eppendorf tube with EGF-Alexa Fluor488 
ligand (2µgml-1 EGF-Alexa488; Invitrogen) in serum free media for 5, 15 or 30 minutes at 
37oC. Control samples were processed without EGF or with cetuximab (25µgml-1; Merck 
Serono, Australia) for 30 minutes followed by EGF-Alexa488 ligand for 15 minutes.  Samples 
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were washed five times with cold PBS containing 0.1% Triton-X-100 (PBTX) for 30 minutes 
and then fixed in 4% paraformaldehyde for 14 hours/overnight at 4oC. Samples were washed 
twice in PBS and placed in 100% methanol (MeOH) at 4oC for 2 hours. Tissue 
autofluorescence was reduced using Dent's bleach (4 MeOH: 1 DMSO: 1 30% H2O2) (Dent et 
al., 1989) for 2 hours at room temperature. Samples were rehydrated using methanol in PBS 
series. Samples were stained with 50mM 4’,6’-diamidino-2-phenylindole (DAPI; Life 
Technologies, Carlsbad, CA) and mounted using ProLong® Gold (Invitrogen) on concave 
microscope slides. Images were acquired using a Zeiss 510 Meta confocal microscope with a 
63x objective and Zen 2008 software (Carl Zeiss, Germany). Photos were taken throughout 
this process and included in Supp. Fig. S2. 
 
Whole mount immunofluorescence of human tumour tissue 
Tumour samples were processed as described above. Following bleaching and rehydration, 
samples were incubated for 4hours in PBTX containing 10% horse serum (blocking buffer) 
and then incubated with anti-EGFR antibody (31G7; Invitrogen), anti-EEA1 antibody (clone 
C45B10; Cell Signalling Technology) or anti-clathrin (clone BF-06; Sapphire Bioscience Pty 
Ltd) diluted in blocking buffer overnight at 4oC. Following 5 x 20 minute washes in PBTX, 
samples were incubated with goat anti-mouse-Alexa Fluor594 secondary antibody (A-11005; 
Invitrogen), anti-rabbit- Alexa Fluor594 (A-11037; Invitrogen) or anti-human Alexa Fluor594 
secondary antibody (A-11014; Invitrogen) diluted in blocking buffer for 1 hour at room 
temperature. Samples were then washed in PBST prior to incubation with DAPI for 10 
minutes, washed and then mounted and imaged as described above.   
 
Analysis of AK, IEC and cSCC tumour samples 
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Patients with biopsy-proven squamous neoplastic skin lesions provided written informed 
consent for their tissue to be used in this study.  23 ex-vivo tumour samples were included 
from 21 patients.  Patient characteristics and demographics are described in the 
Supplementary Table S1, S2 and S3. Tumour samples were collected at surgery in 0.9% NaCl 
(‘normal saline’) and kept on ice during transportation to anatomical pathology where 
samples were immediately sectioned by an experienced dermatopathologist.  A narrow 
transverse section and portion of marginal (normal) skin was taken for assay and the 
remainder was processed for routine histopathology.  Time taken from excision of specimen 
to beginning tumour preparation in the laboratory was no more than 30 minutes and usually 
less.  EGF-Alexa488 ligand uptake assays were completed as described above and compared to 
H&E staining. Ethics approvals listed above.  
 
Super-resolution microscopy 
For three dimensional structured illumination microscopy (3D-SIM), images were captured 
on a Deltavision OMX V3 Imaging System (Applied Precision), EMCCD cameras (CascadeII 
512x512 Photometrics) and using a 60x 1.4-NA UPlanSApo oil-immersion objective 
(Olympus) with oil of a refractive index of 1.524. Images were acquired with a Z-step 
0.125µm with 23-53 steps over thickness of 3-6.5µm at a laser power of 10%. Images were 
computationally reconstructed using Deltavision SoftWorX6.0 Beta19 (Applied Precision) 
(Huang et al., 2009). 
 
COI: FS is discoverer on patents 2015WO2014063206-A1 and 2015WO2014063205-A1. 
 
Acknowledgements 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
20 
 
The authors acknowledge the TRI for providing the excellent research environment and 
Microscopy and Histology Core Facilities. We also acknowledge the funding support 
provided by an NHMRC CDA to FS, Cancer Council Queensland (#1041390), the 
Queensland Head and Neck Cancer Centre, Rotary International (Nundah) and the Princess 
Alexandra Hospital Research Foundation (#2016030) to FS. We also acknowledge the 
funding support provided by an APA scholarship and UQDI RHD scholarship for DG. 
 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
21 
 
References 
 
Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. The British journal of 
dermatology 2006;155(1):9-22. 
Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed 
loops. Nat Rev Mol Cell Biol 2011;12(2):104-17. 
Belleudi F, Scrofani C, Torrisi MR, Mancini P. Polarized endocytosis of the keratinocyte growth factor 
receptor in migrating cells: role of SRC-signaling and cortactin. PLoS One 2011;6(12):e29159. 
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for 
squamous-cell carcinoma of the head and neck. The New England journal of medicine 
2006;354(6):567-78. 
Brand TM, Iida M, Li C, Wheeler DL. The nuclear epidermal growth factor receptor signaling network 
and its role in cancer. Discov Med 2011;12(66):419-32. 
Canueto J, Cardenoso E, Garcia JL, Santos-Briz A, Castellanos-Martin A, Fernandez-Lopez E, et al. 
Epidermal growth factor receptor expression is associated with poor outcome in cutaneous 
squamous cell carcinoma. The British journal of dermatology 2017;176(5):1279-87. 
Ch'ng S, Low I, Ng D, Brasch H, Sullivan M, Davis P, et al. Epidermal growth factor receptor: a novel 
biomarker for aggressive head and neck cutaneous squamous cell carcinoma. Hum Pathol 
2008;39(3):344-9. 
Chua J, Rikhy R, Lippincott-Schwartz J. Dynamin 2 orchestrates the global actomyosin cytoskeleton 
for epithelial maintenance and apical constriction. P Natl Acad Sci USA 2009;106(49):20770-
5. 
Chung BM, Raja SM, Clubb RJ, Tu C, George M, Band V, et al. Aberrant trafficking of NSCLC-associated 
EGFR mutants through the endocytic recycling pathway promotes interaction with Src. BMC 
Cell Biol 2009;10:84. 
Dent JA, Polson AG, Klymkowsky MW. A whole-mount immunocytochemical analysis of the 
expression of the intermediate filament protein vimentin in Xenopus. Development 
1989;105(1):61-74. 
Echejoh Ga, Hu L, Gonzalez Cruz JL, Barry R, O’Donnell JS, Joseph SR, et al. Dynamin inhibition 
increases antibody dependent cellular cytotoxicity in response to monoclonal antibody 
therapy and reverses innate resistance to cetuximab in murine models. Submitted 2018. 
Elkin SR, Lakoduk AM, Schmid SL. Endocytic pathways and endosomal trafficking: a primer. Wien 
Med Wochenschr 2016. 
Feigin ME, Muthuswamy SK. ErbB receptors and cell polarity: new pathways and paradigms for 
understanding cell migration and invasion. Experimental cell research 2009;315(4):707-16. 
Foote MC, McGrath M, Guminski A, Hughes BG, Meakin J, Thomson D, et al. Phase II study of single 
agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Annals 
of oncology : official journal of the European Society for Medical Oncology / ESMO 2014. 
Gaffney DC, Soyer HP, Simpson F. The epidermal growth factor receptor in squamous cell carcinoma: 
An emerging drug target. The Australasian journal of dermatology 2014;55(1):24-34. 
Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth 
factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. 
Cancer Res 1993;53(15):3579-84. 
Groves RW, Allen MH, MacDonald DM. Abnormal expression of epidermal growth factor receptor in 
cutaneous epithelial tumours. Journal of cutaneous pathology 1992;19(1):66-72. 
Hara M, Nakanishi H, Tsujimura K, Matsui M, Yatabe Y, Manabe T, et al. Interleukin-2 potentiation of 
cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric 
cancer xenografts through antibody-dependent cellular cytotoxicity. Cancer Sci 
2008;99(7):1471-8. 
Helman EE, Newman JR, Dean NR, Zhang W, Zinn KR, Rosenthal EL. Optical imaging predicts tumor 
response to anti-EGFR therapy. Cancer Biol Ther 2010;10(2):166-71. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
22 
 
Huang B, Bates M, Zhuang X. Super-resolution fluorescence microscopy. Annu Rev Biochem 
2009;78:993-1016. 
Jost M, Kari C, Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. 
European journal of dermatology : EJD 2000;10(7):505-10. 
Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibody-dependent 
cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. 
International journal of cancer Journal international du cancer 2007;120(4):781-7. 
Kikuchi A, Amagai M, Hayakawa K, Ueda M, Hirohashi S, Shimizu N, et al. Association of EGF receptor 
expression with proliferating cells and of ras p21 expression with differentiating cells in 
various skin tumours. The British journal of dermatology 1990;123(1):49-58. 
Kim DH, Kim DK, Zhou K, Park S, Kwon Y, Jeong MG, et al. Single particle tracking-based reaction 
progress kinetic analysis reveals a series of molecular mechanisms of cetuximab-induced 
EGFR processes in a single living cell. Chem Sci 2017;8(7):4823-32. 
Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Antibody-dependent cellular 
cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth 
factor receptor. Cancer Sci 2007;98(8):1275-80. 
Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein 
interactions. Biochem J 2000;351 Pt 2:289-305. 
Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, et al. Antibody-dependent cellular 
cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 
2007;13(5):1552-61. 
Lavrijsen AP, Tieben LM, Ponec M, van der Schroeff JG, van Muijen GN. Expression of EGF receptor, 
involucrin, and cytokeratins in basal cell carcinomas and squamous cell carcinomas of the 
skin. Archives of dermatological research 1989;281(2):83-8. 
Liu B, Zhang H, Li S, Chen W, Li R. The expression of c-erbB-1 and c-erbB-2 oncogenes in basal cell 
carcinoma and squamous cell carcinoma of skin. Chinese medical sciences journal = Chung-
kuo i hsueh k'o hsueh tsa chih / Chinese Academy of Medical Sciences 1996;11(2):106-9. 
McCluskey A, Daniel JA, Hadzic G, Chau N, Clayton EL, Mariana A, et al. Building a better dynasore: 
the dyngo compounds potently inhibit dynamin and endocytosis. Traffic 2013;14(12):1272-
89. 
Mellman I, Yarden Y. Endocytosis and cancer. Cold Spring Harbor perspectives in biology 
2013;5(12):a016949. 
Mutch LJ, Howden JD, Jenner EP, Poulter NS, Rappoport JZ. Polarised clathrin-mediated endocytosis 
of EGFR during chemotactic invasion. Traffic 2014;15(6):648-64. 
Nazmi MN, Dykes PJ, Marks R. Epidermal growth factor receptors in human epidermal tumours. The 
British journal of dermatology 1990;123(2):153-61. 
Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization 
in development and cancer. EMBO J 2000;19(13):3159-67. 
Pastore S, Mascia F, Mariani V, Girolomoni G. The epidermal growth factor receptor system in skin 
repair and inflammation. The Journal of investigative dermatology 2008;128(6):1365-74. 
Pinilla-Macua I, Grassart A, Duvvuri U, Watkins SC, Sorkin A. EGF receptor signaling, phosphorylation, 
ubiquitylation and endocytosis in tumors in vivo. Elife 2017;6. 
Pinilla-Macua I, Sorkin A. Methods to study endocytic trafficking of the EGF receptor. Methods Cell 
Biol 2015;130:347-67. 
Stintzing S, Zhang W, Heinemann V, Neureiter D, Kemmerling R, Kirchner T, et al. Polymorphisms in 
Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. 
Mol Cancer Ther 2015;14(10):2374-81. 
Teis D, Huber LA. The odd couple: signal transduction and endocytosis. Cell Mol Life Sci 
2003;60(10):2020-33. 
Van den Eynde M, Baurain JF, Mazzeo F, Machiels JP. Epidermal growth factor receptor targeted 
therapies for solid tumours. Acta Clin Belg 2011;66(1):10-7. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
23 
 
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based 
chemotherapy plus cetuximab in head and neck cancer. The New England journal of 
medicine 2008;359(11):1116-27. 
Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future 
treatment strategies. Nat Rev Clin Oncol 2010;7(9):493-507. 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
24 
 
Figure Legends 
Table 1. Summary of advanced SCC lesions, EGF internalization status and anti-EGFR 
therapy outcome. 11/24 samples able to be assessed for EGF ligand uptake were classified as 
dysregulated.  
De-identified 
patient code 
SCC type EGF Trafficking status* Anti-EGFR treatment and 
outcome* 
RW2 Head and Neck Dysregulated ND, No anti-EGFR treatment 
JT3 Head and Neck Dysregulated ND, No anti-EGFR treatment 
DP5 Head and Neck Dysregulated Cmab, Alive, complete response 
BV8 Head and Neck Dysregulated ND, No anti-EGFR treatment 
JM2P Cutaneous Dysregulated ND, No anti-EGFR treatment 
EG7 Head and Neck Internalized Cmab, Dead with disease 
SW1P Cutaneous Internalized ND, No anti-EGFR treatment 
AC3P Cutaneous Internalized ND, No anti-EGFR treatment 
AM1GP Head and Neck Internalized Cmab, Dead with disease 
GD12 Head and Neck Internalized Cmab, Dead with disease 
RA11 Head and Neck Internalized Cmab, Dead with disease 
LB10 Head and Neck Internalized Cmab, Dead with disease 
PAH001 Cutaneous Internalized Pmab, rash,  Dead with disease 
PAH002 Cutaneous Internalized Pmab, rash, Dead with disease 
PAH003 Cutaneous Dysregulated Pmab, rash, Alive with disease 
PAH004 Cutaneous Internalized Pmab, no rash, Dead with disease 
PAH005 Cutaneous ND Pmab, rash, Dead with disease 
PAH006 Cutaneous Dysregulated Pmab, rash, Dead with disease: not 
SCC but renal failure after previous 
transplant. 
PAH007 Cutaneous Internalized Pmab, rash, Dead with disease 
PAH008 Cutaneous Dysregulated Pmab, rash, Alive with disease 
PAH009 Cutaneous Dysregulated Pmab, rash, Alive, no evidence of 
disease, complete response. 
PAH010 Cutaneous ND Pmab, rash, Dead with disease 
Best response was PD at 2 weeks and 
treatment ceased. 
PAH011 Cutaneous ND Pmab, rash, Dead with disease 
PAH012 Cutaneous Internalized Pmab, rash, Dead with disease 
PAH013 Cutaneous Internalized Pmab, rash, Dead with disease 
PAH014 Cutaneous ND Pmab, rash, Alive with disease 
PAH015 Cutaneous Dysregulated Pmab, rash, Alive with stable disease 
PAH016 Cutaneous Dysregulated Pmab, rash, Alive with stable disease 
* ND - not determined; Cmab – cetuximab; Pmab – panitumumab; 
Figure 1. Comparison between conventional pathology imaging and confocal imaging of 
human tissue samples.  (a) Comparison of H&E staining and immunofluorescent labelling 
by confocal microscopy (tile scan) of an invasive SCC. Nuclear disorganization and invasion 
can be seen clearly in the confocal image where nuclei (DAPI; blue) corresponded to 
dysplasia seen by H&E. (scale bar, 200 µm) (b) Dysplastic cells within SCC AC3P and DP5 
samples over-expressed the EGFR. H&E staining of 4µm sections from patient tumours taken 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
25 
 
at 4x magnification (top, Scale bar, 200 µm). Below images are 25x magnification of region 
indicated by white box in panels above. Successive sections of SCC AC3P and SCC DP5 
fluorescently labeled with anti-EGFR (anti-mouse Alexa488 secondary; green) and DAPI 
(blue). Scale bars, 50µm.  
 
Figure 2.  Ligand-induced EGFR endocytosis is dysregulated in advanced SCC. (a) EGF-
Alexa488 (green) uptake distribution in tumour (AC3P) SCC after 15min and 30min 
stimulation. Magnification of boxed region shown in insert. Uptake of EGF is observed as 
punctate fluorescence. Scale bars, 20µm. (b) EGF-Alexa488 (green) uptake distribution in 
tumour (DP5). Plasma membrane binding of EGF-Alexa488 is observed but little 
internalization. 30min EGF-Alexa488 incubation in matched normal epithelial tissue also 
shown. Scale bars, 20µm. (c) Super-resolution microscopy of human SCC in which EGFR 
does not undergo normal ligand-induced internalization (Dysregulated; top, SCC DP5) or 
retains ligand-induced internalization (Internalizing; bottom, SCC AC3P). Different 
distributions of EGF-Alexa488 between the two samples are observed. Blue dotted lines 
indicate nucleus. Scale bars, 5µm. 
 
Figure 3. EGF ligand uptake can be analyzed in ex-vivo tumours. In all images nuclei are 
stained with DAPI (blue) (a) Post-fixation labeling of EGFR (31G7, anti-mouse Alexa594; 
red) co-localizes with EGF-Alexa488 ligand uptake (30min; green, pre-fixation) in 
dysregulated lesion. (b) Pre-treatment of dysregulated lesion with cetuximab prior to EGF-
Alexa488 (green) addition blocks EGF binding. Post-fixation labeling of cetuximab, anti-
human Alexa594 secondary (red). (c) EGF-Alexa488 (green) and DEAE-Dextran-Alexa555(red) 
uptake after 30min incubation in internalizing (left) or endocytically dysregulated lesions 
(right). Arrows indicate co-localization. (d) EEA1 (anti-rabbit Alexa594; red) and EGF-
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Alexa488 (green; 30min uptake) in internalizing (left) and endocytically dysregulated patient 
lesions (right). Arrows indicate co-localization. (e) Clathrin (anti-mouse Alexa594; red) and 
EGF-Alexa488 (green; 15min uptake) in internalizing (left) and dysregulated patient lesion 
(right). Scale bars, 20µm 
 
Figure 4. Pattern of EGF-Alexa488 uptake in the basal layers and at the leading edges in 
early SCC lesions. Following EGF-Alexa488 incubation various EGF ligand localization 
subtype patterns were seen in AK, IEC and cSCC. In some lesions, EGFR was internalized in 
response to EGF-Alexa488 ligand stimulation (Internalizing; lesion 18, lesion 11 and lesion 8), 
while in others, no ligand-induced receptor-mediated endocytosis occurred (Dysregulated; 
lesion 3, lesion 7 and lesion 20).  In some lesions EGF-Alexa488 was polarized to leading 
edges of SCC and in some it was not. The cartoon on right summarizes the EGF ligand 
localization pattern subtype. Lesion data is summarized in Supp. Table S3. Scale bars, 20µm.  
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